In HCC cells, MK2 inhibition promotes TTP function, thus reducing the expression of target genes (i.e., c-MYC, IER3 (Immediate Early Response 3), AKT-1) and triggering apoptosis [73]. The gene discussed is IER3; the disease is hepatocellular carcinoma.